Despite these challenges, ongoing advances in ILC biology across autoimmune and inflammatory diseases offer exciting opportunities for precision immunotherapy and the following sections examine the roles of ILCs in T1D, MS, SLE, AAV, RA, SSc, and IBD, highlighting both disease-specific mechanisms and broader immunological themes (Table 1). This evidence concerns the gene CCL27 and systemic lupus erythematosus.